solidbio.com (SLDB): Operating Profitability

Corporate company logo of Solid Biosciences Inc. (SLDB)

Solid Biosciences Inc. (SLDB) relies entirely on third-party contractors for the production of viral vectors. Monitoring of operating profitability reflects the dynamics of these costs, with the value stabilizing at 0.00. The company is developing breakthrough treatments for muscular dystrophy by replacing damaged genes. A strong patent portfolio creates a technological advantage that will become a full-fledged financial asset upon the completion of clinical trials.

SLDB: solidbio.com Operating Sales Margin 07/04/2022 - 11/19/2026

SLDB (Solid Biosciences): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company valuation:Solid Corp, SLDB
Core merchandise of solidbio.com

This ratio mathematically determines the efficiency of cost management relative to sales volume. The operating margin expresses the share of profit from the core business before taxes and interest payments as a percentage of total revenue. For Solid Biosciences (SLDB), which is developing gene therapy, this metric reflects the cost of clinical development prior to the commercialization of drugs. Analyzing the operating margin allows for an assessment of the sustainability of the innovation financing model. A decline in this indicator signals rising operating expenses.

Competitor analysis

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability